Johnson & Johnson (JNJ) Equity Average (2009 - 2026)

Johnson & Johnson has disclosed Equity Average across 18 years of filings, most recently posting $81.4 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $81.4 billion, up 8.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.4 billion (up 8.78% YoY), and the FY2025 annual result was $76.5 billion, up 9.1% from the prior year.
• Equity Average came in at $81.4 billion for Q1 2026 at Johnson & Johnson, up from $80.4 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $81.4 billion in Q1 2026 to a low of $69.4 billion in Q1 2024.
• The 5-year median for Equity Average is $74.1 billion (2022), against an average of $74.5 billion.
• Across the five-year window, Equity Average climbed 15.2% in 2022 and dropped 7.53% in 2023, its largest moves.
• Johnson & Johnson's Equity Average stood at $75.5 billion in 2022, then declined by 7.26% to $70.0 billion in 2023, then climbed by 1.18% to $70.8 billion in 2024, then gained by 13.54% to $80.4 billion in 2025, then grew by 1.19% to $81.4 billion in 2026.
• The last three Equity Average figures came in at $81.4 billion (Q1 2026), $80.4 billion (Q4 2025), and $78.9 billion (Q3 2025), per Business Quant data.